REG - Adv Medical Solutns. - Director/PDMR Shareholding

Advanced Medical SolutionsAnnouncement

26/04/2024 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240426:nRSZ2070Ma&default-theme=true

RNS Number : 2070M  Advanced Medical Solutions Grp PLC  26 April 2024

     26 April 2024

            Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

 

            Director/PDMR Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, announces that on 23
April 2024, the Board, following a recommendation from its Remuneration
Committee, granted new nil-cost share options to the following Directors/PDMRs
under the existing Advanced Medical Solutions Long Term Incentive Plan (the
'LTIP'). The vesting of these options is based on achieving certain
performance criteria for the three years prior to vesting. The performance
criteria under the LTIP scheme is split equally between Earnings Per Share
(EPS) achievement against target and Total Shareholder Return (TSR) against a
comparator group.  Directors/PDMRs are required to hold the LTIPs for a
period of two years following vesting.

 

 Director/PDMR             LTIPs prior to grant  LTIPs granted  Resultant LTIP holdings
 Chris Meredith            935,567               411,478        1,347,045

 Chief Executive Officer
 Eddie Johnson             417,032               169,837        586,869

 Chief Financial Officer

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Chris Meredith
 2.  Reason for the notification
 a)  Position/status: Chief Executive Officer
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     -     Grant of options under the Advanced Medical Solutions Long Term
     Incentive Plan
 c)  Price(s) and volume(s):

     Sale of shares:

Price(s)  Volume(s)
     1. -      411,478
 d)  Aggregated information:

     Aggregated volume: n/a

     Aggregated price: n/a
 e)  Date of the transaction: 23/04/2024
 f)  Place of the transaction: Outside of a trading venue

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 23/04/2024

f)

Place of the transaction: Outside of a trading venue

 

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Eddie Johnson
 2.  Reason for the notification
 a)  Position/status: Chief Financial Officer
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     -     Grant of LTIPs under the Advanced Medical Solutions Long Term
     Incentive Plan
 c)  Price(s) and volume(s):

     Sale of shares:

Price(s)  Volume(s)
     1. -      169,837
 d)  Aggregated information:

     Aggregated volume: n/a

     Aggregated price: n/a
 e)  Date of the transaction: 23/04/2024
 f)  Place of the transaction: Outside of a trading venue

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 23/04/2024

f)

Place of the transaction: Outside of a trading venue

 

 

- End -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc            Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 ICR Consilium                                   Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Lucy Featherstone           AMS@consilium-comms.com

 Investec Bank PLC (NOMAD & Broker)              Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 HSBC Bank PLC (Broker)                          Tel: 44 (0) 20 7991 8888
 Sam McLennan / Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

 

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®) and Seal-G(®). AMS also supplies wound care dressings such
as silver alginates, alginates and foams through its ActivHeal(®) brand as
well as under white label. Since 2019, the Group has made five acquisitions:
Sealantis, an Israeli developer of innovative internal sealants; Biomatlante,
a French developer and manufacturer of surgical biomaterials, Raleigh, a
leading UK coater and converter of woundcare and bio-diagnostics materials,
AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish
tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the
Czech Republic and Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia. The Group has
R&D innovation hubs in the UK, Ireland, Germany, France and Israel.
Established in 1991, the Group has more than 900 employees. For more
information, please see www.admedsol.com (http://www.admedsol.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHGIGDSUBDDGSL